Through the formation of a "target protein-PROTAC-E3 ligase" complex, the affinity between MCL-1 and the E3 ligase CRBN is effectively enhanced, which selectively degrades MCL-1 to obtain stronger tumor cell killing activity. Here, MCL1 is linked to neoplasm.